Anbio Biotechnology (NNNN) CEO Michael Lau identified as insider in Form 3

Rhea-AI Filing Summary

Anbio Biotechnology CEO Michael Lau has filed an initial Form 3 as an officer of the company. This filing identifies him as the Chief Executive Officer but, in this excerpt, shows no reportable holdings or insider transactions in Anbio Biotechnology securities at the time of the filing.

Key Figures

Buy transactions reported: 0 transactions Sell transactions reported: 0 transactions Derivative transactions reported: 0 transactions

3 metrics

Buy transactions reported 0 transactions Form 3 transaction summary

Sell transactions reported 0 transactions Form 3 transaction summary

Derivative transactions reported 0 transactions Form 3 derivativeTransactionCount

Key Terms

Form 3, reporting person, beneficial ownership

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

"reportingPersons"

beneficial ownership financial

"initial statement of beneficial ownership"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

LAU MICHAEL

(Last) (First) (Middle)

FRIEDRICH-EBERT-ANLAGE 35-37

(Street)

FRANKFURT AM MAIN 60327

(City) (State) (Zip)

GERMANY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Anbio Biotechnology [ NNNN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Michael Lau	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Anbio Biotechnology (NNNN) CEO Michael Lau’s Form 3 show?

The Form 3 identifies Michael Lau as Chief Executive Officer of Anbio Biotechnology and a reporting person. In this excerpt, it shows no reportable holdings or insider transactions in the company’s securities at the time of the filing.

Are there any buy or sell transactions for NNNN in this Form 3?

No transactions are reported. The transaction summary shows zero buys, zero sells, and zero derivative exercises, indicating no insider trading activity is disclosed in this Form 3 excerpt for Anbio Biotechnology (NNNN).

Does Michael Lau report any derivatives or options in Anbio Biotechnology (NNNN)?

No derivative positions are shown. The derivative summary is empty and derivativeTransactionCount is zero, indicating no reportable options, warrants, or other derivative securities for Michael Lau in this Form 3 excerpt.

What is the purpose of this Form 3 for Anbio Biotechnology (NNNN)?

This Form 3 serves as an initial statement of beneficial ownership for CEO Michael Lau. It establishes him as a reporting person for Anbio Biotechnology, although this excerpt shows no current holdings or transactions to disclose.

Does the Form 3 for NNNN mention any Rule 10b5-1 trading plans?

The provided data does not reference any Rule 10b5-1 trading plans. The transaction summary lists zero transactions of all types, suggesting no pre-planned or discretionary trading activity is disclosed in this Form 3 excerpt.